secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0001447362-25-000068
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Q1 revenue $88M (+21% YoY), raises FY guidance to $287-297M, acquires Previse
--------------------------------------------------------------------------------

- Q1 revenue $88.0M (+21% YoY); total test reports 24,402 (+17%); core driver reports +33% YoY.
- Net loss $(0.90) per share incl. $20.1M amortization acceleration; adjusted net loss $(0.20); Adj. EBITDA $13.0M.
- FY 2025 revenue guidance raised to $287-297M from prior $280-295M.
- Signed definitive agreement to acquire Previse, a GI health company focused on esophageal cancer; no terms disclosed.
- DecisionDx-Melanoma surpassed 200,000 test orders; IDgenetix test to be discontinued effective May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000068/0001447362-25-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000068/cstl-20250505.htm
  HTML page:      https://secwatch.observer/filing/0001447362-25-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer